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LETTER TO THE EDITOR
BIOHYBRID – Biohybrid templates for peripheral nerve
regeneration
Dear Editor,
Peripheral nerve injuries represent a major cause
for morbidity and disability in affected patients and
cause substantial costs for society in a global perspec-
tive. It has been estimated that peripheral nerve injuries
affect 2.8% of trauma patients, many of whom acquire
life-long disability (Noble et al., 1998). With respect to
an incidence of nerve injuries of 13.9/100,000 inhabi-
tants per year (Asplund et al., 2009) and the number
of inhabitants in the EU (495,000,000 inhabitants in
2007), the number of peripheral nerve injuries requiring
repair and reconstruction, excluding nerve injuries by
amputations, may be 70,000 annually only in EU coun-
tries. Related to peripheral nerve injuries, the costs for
society are substantial and consist of direct (costs for
surgery, outpatient visits and rehabilitation) and indi-
rect (lost production) costs. Individual median and ulnar
nerve injuries in the forearm have total costs of EUR
51,000 and 31,000, respectively, where around 85% of
the costs consist of loss of production (Rosberg et al.,
2005), still excluding costs for adjusted quality of life
(Eriksson et al., 2011). Thus, one may estimate that
the annual costs only in the EU may be as high as EUR
2.2 billion, indicating that improved treatment strate-
gies for peripheral nerve injuries may not only improve
the situation for patients, but may also significantly
reduce costs for society.
Based on these premises, the EU granted a
6,000,000 Euro fund as part of the seventh Framework
Program to the BIOHYBRID consortium that was built
with the overall aim to develop, in a pre-clinical per-
spective, an innovative biohybrid artificial nerve device
for improving the regenerative treatment of severe
traumatic injuries of peripheral nerves.
BIOHYBRID is a 4-year collaborative project that
AQ1
started on October 1, 2011, and involves 10 part-
ners from 5 European Countries (Germany, Italy,
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Portugal, Spain and Sweden) and1 Associate Coun-
try (Israel) (Fig. 1). The Consortium, coordinated by
Claudia Grothe from Hannover Medical School and
supported by a coordination board composed of Ste-
fano Geuna from Turin University, Thomas Freier from
Medovent GmbH, and Kirsten Haastert-Talini also from
Hannover Medical School, includes three active and
well-integrated SMEs as well as seven academic part- AQ2
ners covering all the scientific areas of interest for this
project.
The work program includes an integrated
experimental approach bringing together the main
aspects of regenerative medicine: (1) reconstructive
microsurgery, (2) regenerative scaffolds, and (3) cell
transplantation. This approach aims at the biologi-
cal pre-fabrication of biohybrid nerve devices, their
grafting into nerve gaps in various animal models,
and the comprehensive evaluation of the regenera-
tive outcome. The SME involvement is not limited to
production and supply of materials and services but
also includes active participation in conduction of the
experiments for in vivo pre-clinical assessment and
follow-up.
The project is built on seven work packages
(WPs). The first (WP1) is focused on the optimization
and evaluation of chitosan-based hollow tubes with
different characteristics, including porosity, biocom-
patibility, and biodegradability. Following initial material
assessment according to standardized ISO/EN 109935
guidelines, different primary cell types (sensory, motor
neurons, Schwann cells, human mesenchymal stem
cells) will be seeded into the hollow devices and ana-
lyzed with regard to cell survival, neurite outgrowth,
cell differentiation, and myelination under standardized
conditions.
Selected conditions will then be used in a
standardized in vivo rat model for peripheral nerve
regeneration (10 mm gap in sciatic nerves of adult
rats) studied with regard to morphological and
functional regeneration under standardized conditions
(e.g., behavioral tests, electrophysiology, nerve
morphometry, immunohistochemistry, biochemistry,
molecular biology, etc.).
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Figure 1. The BIOHYBRID Consortium as a whole.
The following two steps (WP2/WP3) aim at
defining efficient strategies for improving the effec-
tiveness of the tubular devices obtained in WP1.
This will be obtained either along two strate-
gies: (1) functionalization by luminal fillers/biomatrices
and/or trophic factors conjugated to nanoparti-
cles (WP2); (2) enrichment with primary cell types
(Schwann cells and mesenchymal stem cells) geneti-
cally engineered to promote neurite outgrowth by the
production of neurotrophic factors (WP3). Based on
extensive in vitro testing, the combined devices that
prove to perform best will be selected for in vivo evalu-
ation following the same experimental protocols used
in WP1.
As a final comparative evaluation aiming at defining
the best approach among those that emerged as the
most effective in WP1-3, WP4 is focused on their
in vivo assessment in more complex sciatic nerve
repair animal models, including (1) a rat model with
long gap (15 mm), with/without delayed repair; (2) a
diabetic rat model with moderate increased glycemic
levels; and (3) a rabbit model with 4 cm sciatic nerve
gap.
Furthermore, the presence of substantiated
expertise to meet the regulatory work for ATMP
development inside the Consortium will result in the
continuous supervision of the facilitation of product
transfer into future clinical trials (WP5). This WP
includes the development of new documentation
models, health economy calculations, standard
operation protocols, consultation of the Innovation
Task Force and the Committee for Advanced Therapies
(CAT) for scientific advice and for classification of the
product, design of Common Technical Documents for
GMP manufacture and of dossiers for clinical trial
authorization by the national regulatory authorities, and
preparation of submission of quality and non-clinical
data (conducted under GLP conditions) to EMA/CAT AQ3
for ATMP certification.
Finally, management of the project activities as
well as the dissemination and exploitation of the
project results will be carried out according to two
dedicated WPs (WP6 and WP7).
BIOHYBRID is an academic–industrial partnership
AQ4
reaching to significant innovation in peripheral nerve
AQ5
tissue engineering with considerable funding from the
EU. A side objective of this project is also to generate a
protocol that can serve as a template for future clinical
trials for tissue engineering of damaged peripheral
nerves. Considering the interdisciplinary expertise of
the project partners, the BIOHYBRID project stands on
the front line of regenerative medicine research and it
is expected that it can lead to significant advancements
regarding not only the biology of nerve regeneration
but also the clinical treatment of patients suffering
from peripheral nerve damage.
Sincerely,
Claudia Grothe1, K. Haastert-Talini1, T. Freier2, X.
Navarro3, L. B. Dahlin4, A. Salgado5, S. Rochkind6, A.
Shahar7 , L. F. V. Pinto8, M. Hildebrandt9, and S.
Geuna10
1Hannover Medical School; 2Medovent GmbH,
Mainz, Germany; 3Universitat Auto`noma de
Barcelona, Bellaterra, Spain; 4Lund University,
Sweden; 5Universidade do Minho, Portugal; 6Tel Aviv
Sourasky Medical Center; 7N.V.R Research LTD,
Ness-Ziona, Israel; 8Altakitin S.A., Portugal;
9Technische Universita¨t, Mu¨nchen, Germany;
10University of Turin, Italy
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QUERIES TO BE ANSWERED BY AUTHOR
IMPORTANT NOTE: Please mark your corrections and answers to these queries directly onto the proof at
the relevant place. DO NOT mark your corrections on this query sheet.
Queries from the Copyeditor:
AQ1. Please provide fax number for the corresponding author.
AQ2. Please define ‘‘SME’’.
AQ3. Please define ‘‘ GLP’’.
AQ4. Please expand the first names of all authors.
AQ5. Please provide the department names in all affiliations, if available.
